256376-24-6

Basic information

• Product Name: BAY 41-2272
• Synonyms: 5-Cyclopropyl-2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-4-pyriMidinaMine;5-Cyclopropyl-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyrimidin-4-amine
• CAS NO: 256376-24-6
• Molecular Formula: C₂₀H₁₇FN₆
• Molecular Weight: 360.394
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals, Inhibitors
• Mol File: 256376-24-6.mol

Chemical Properties

• Melting Point: 210.5-211.4 °C
• Boiling Point: 496.08°C at 760 mmHg
• Flash Point: 253.82°C
• Appearance: white/solid
• Density: 1.494g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.767
• Storage Temp.: 2-8°C
• Solubility: DMSO: 26 mg/mL at 60 °C
• PKA: 2.71±0.10(Predicted)
• CAS DataBase Reference: BAY 41-2272(CAS DataBase Reference)
• NIST Chemistry Reference: BAY 41-2272(256376-24-6)
• EPA Substance Registry System: BAY 41-2272(256376-24-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 256376-24-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BAY 41-2272 is used as a soluble guanylate cyclase agonist for activating human mononuclear phagocytes and inhibiting vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.
Used in Cardiovascular Applications:
BAY 41-2272 is used as a therapeutic agent for treating various cardiovascular conditions in animal models. It is effective in reducing mean arterial blood pressure in hypertensive rats and has shown to inhibit platelet aggregation and induce relaxation of phenylephrine-preconstricted rabbit aorta rings.
Used in Research and Development:
BAY 41-2272 is used as a research tool for studying the role of soluble guanylate cyclase in various biological processes and its potential as a therapeutic target for cardiovascular diseases.

Biochem/physiol Actions

Cell permeable: yes

InChI:InChI=1/C20H17FN6/c21-16-6-2-1-4-13(16)11-27-20-14(5-3-9-23-20)17(26-27)19-24-10-15(12-7-8-12)18(22)25-19/h1-6,9-10,12H,7-8,11H2,(H2,22,24,25)

Upstream product

• 256376-68-8 please input 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine 
• 6542-60-5 2-cyclopropylacetonitrile 
• 51859-98-4 (2-fluorobenzyl)hydrazine 
• 256376-57-5 2-cyclopropyl-3-dimethylaminoacrylonitrile 
• 256376-79-1 2-cyclopropyl-3-oxo-propionitrile 
• 256376-59-7 ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 
• 304874-06-4 methyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbimidate 
• 256376-62-2 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
• 256504-39-9 ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate 
• 256376-65-5 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 

Relevant articles and documents

NO-independent stimulators of soluble guanylate cyclase

SARs around a novel type of guanylate cyclase stimulator which act by a mechanism different from classical NO-donors are described. Several pyrazolopyridinylpyrimidines are shown to relax aortic rings and revealed a long-lasting blood pressure lowering effect in rats after oral application.

Substituted pyrazole derivatives

The present invention relates to novel substituted pyrazole derivatives of the general formula (I) in which the substituents R1, R2, R3, A, X and Y are each as defined, and to processes for their preparation and to their use as medicaments, in particular as medicaments for the treatment of cardiovascular disorders.